Oppenheimer Maintains Outperform on Biogen, Lowers Price Target to $255
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Jay Olson maintains an Outperform rating on Biogen but lowers the price target from $270 to $255.
October 31, 2024 | 6:09 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Oppenheimer has maintained its Outperform rating on Biogen but has reduced the price target from $270 to $255, indicating a slightly less optimistic outlook.
The maintenance of an Outperform rating suggests continued confidence in Biogen's performance, but the lowered price target indicates a tempered outlook. This mixed signal may result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100